Mark F. Kubik
Corporate Officer/Principal at GENOR BIOPHARMA HOLDINGS LIMITED
Profile
Mark F.
Kubik is currently the Chief Business Officer at Genor Biopharma Holdings Ltd.
He previously worked as the Head of Business Development at Merck & Co., Inc., and as the Chief Business Officer at Actinium Pharmaceuticals, Inc. and OncoImmune, Inc. Kubik received his undergraduate degree from the University of Colorado Boulder and his MBA from The Leeds School of Business.
Mark F. Kubik active positions
Companies | Position | Start |
---|---|---|
GENOR BIOPHARMA HOLDINGS LIMITED | Corporate Officer/Principal | 16/08/2021 |
Former positions of Mark F. Kubik
Companies | Position | End |
---|---|---|
OncoImmune, Inc.
OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD. | Corporate Officer/Principal | - |
MERCK & CO., INC. | Corporate Officer/Principal | - |
ACTINIUM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Training of Mark F. Kubik
University of Colorado Boulder | Undergraduate Degree |
The Leeds School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
GENOR BIOPHARMA HOLDINGS LIMITED | Health Technology |
Private companies | 1 |
---|---|
OncoImmune, Inc.
OncoImmune, Inc. Pharmaceuticals: MajorHealth Technology OncoImmune, Inc. engages in the research and development of biopharmaceuticals for the treatment of cancer and autoimmune diseases. It offers CD24Fc, a recombinant fusion protein that targets a novel immune pathway checkpoint; Sialidase Inhibitors, ONC-392, and Echinomycin. The company was founded by Kun-Liang Guan, Ming You, Yang Liu, and Pan Zheng in 2000 and is headquartered in Rockville, MD. | Health Technology |
- Stock Market
- Insiders
- Mark F. Kubik